Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10701MR)

This product GTTS-WQ10701MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10701MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15977MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ756MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ13317MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10550MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ7379MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ13206MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ1124MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ15242MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW